SpringWorks Therapeutics Inc (SWTX)
44.86
+0.09
(+0.20%)
USD |
NASDAQ |
May 17, 16:00
44.86
0.00 (0.00%)
After-Hours: 20:00
SpringWorks Therapeutics Research and Development Expense (Annual): 150.49M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 150.49M |
| December 31, 2022 | 146.12M |
| December 31, 2021 | 101.68M |
| Date | Value |
|---|---|
| December 31, 2020 | 51.86M |
| December 31, 2019 | 42.54M |
| December 31, 2018 | 9.898M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
42.54M
Minimum
2019
150.49M
Maximum
2023
98.54M
Average
101.68M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Geron Corp | 125.05M |
| Verastem Inc | 61.36M |
| Karyopharm Therapeutics Inc | 138.75M |
| Syndax Pharmaceuticals Inc | 163.03M |
| Arvinas Inc | 379.70M |